Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Not yet enrolling; Phase 4

Conditions: Thyroid Neoplasm Follicular; Bone Metastases

Treatments: Drug: Sr-89

Study type: Interventional

Funder types: Other

Identifiers

NCT05466812

ZS-3477

Details and patient eligibility

About

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Full description

Using biochemical markers (such as thyroglobulin), functional markers (such as change of tumor-background ratio on bone scan), etc to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Enrollment: 20 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of differentiated thyroid cancer
• Positive uptake by bone metastases on bone scan
• Planing to have Sr-89 treatment

Exclusion criteria

• Having received treatment for bone metastases within one month of the study (such as radiotherapy, surgery, targeted therapy, chemotherapy, etc., among which denosumab and bisphosphate were allowed as basic treatment)
• Having received radioactive iodine therapy within half a year before the study
• There are bone related events, such as fracture, spinal cord compression, etc.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Sr-89 treated group

Experimental group

Description:

Sr-89 treatment

Treatment:

Drug: Sr-89